This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be available in the United States. Abbott's ARCHITECT HE4 assay uses a simple blood test to help in monitoring for the recurrence or progression of epithelial ovarian cancer. If approved, this important immunoassay would be the first automated HE4 test available in the United States.
We care about your feedback. Let us know how we can improve your CancerCompass experience.